Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABELCET vs EXSEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Invasive fungal infections refractory to amphotericin B deoxycholate or in patients intolerant to that formulation,Aspergillosis,Candidiasis,Cryptococcosis,Blastomycosis,Histoplasmosis,Coccidioidomycosis,Zygomycosis,Fungal sinusitis,Empiric therapy in febrile neutropenic patients (off-label),Visceral leishmaniasis (off-label)
Treatment of tinea versicolor (pityriasis versicolor),Management of dandruff and seborrheic dermatitis of the scalp
5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.
1-2 mg orally once daily; maximum dose 2 mg/day.
Terminal elimination half-life is approximately 120–180 hours (mean ~153 h) in adults with normal renal and hepatic function. This long half-life reflects slow redistribution from tissues and supports once-daily dosing after a loading regimen.
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (Cr Cl <30 m L/min).
Amphotericin B is not significantly metabolized in humans; it is eliminated primarily via biliary excretion with negligible renal metabolism.
Minimal systemic absorption after topical application; any absorbed selenium is primarily excreted in urine, with minor metabolism via reduction to selenides and methylation to dimethylselenide.
Renal excretion is minimal (<1% unchanged drug); the primary route of elimination is via the hepatobiliary system, with the majority of the dose recovered in feces as unchanged drug and metabolites. Biliary/fecal elimination accounts for >90% of clearance.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
More than 99% bound to plasma proteins, primarily to albumin and lipoproteins (e.g., LDL and HDL).
95% bound to albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.5–1.0 L/kg, indicating extensive tissue distribution (e.g., liver, spleen, lung, kidney) with limited penetration into cerebrospinal fluid and vitreous humor.
0.8-1.2 L/kg; indicates extensive extravascular distribution.
Not applicable; only administered intravenously. Oral bioavailability is negligible (less than 5%) due to poor gastrointestinal absorption and degradation in the GI tract.
Oral: 60-80%; first-pass metabolism reduces bioavailability by 20-40%.
No dosage adjustment required, but renal function should be monitored; consider dose adjustment if Cr Cl < 30 m L/min or if significant nephrotoxicity occurs (e.g., doubling of serum creatinine).
No adjustment required for mild to moderate impairment. Severe impairment (GFR <30 m L/min): contraindicated.
No specific adjustment; use with caution in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B or C: contraindicated.
Same dosing as adults (5 mg/kg/day IV); safety and efficacy established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific adjustment, but monitor renal function and electrolyte balance due to higher risk of toxicity.
Start at 1 mg orally once daily; titrate cautiously due to increased risk of falls and hypotension.
WARNING: Should be used primarily for treatment of progressive, potentially life-threatening fungal infections in patients intolerant to conventional amphotericin B deoxycholate or whose infection is refractory to that formulation. Not interchangeable with other amphotericin B products. Verify correct product prior to administration. Administer by intravenous infusion only.
None.
Nephrotoxicity: monitor renal function closely; may cause azotemia, hypokalemia, hypomagnesemia,Hypersensitivity reactions: anaphylaxis, bronchospasm, flushing, hypotension,Infusion-related reactions: fever, chills, rigors, headache, nausea, vomiting,Cardiotoxicity: arrhythmias, cardiac arrest (especially during rapid infusion),Hepatotoxicity: elevated liver enzymes, bilirubin,Hematologic toxicity: anemia, thrombocytopenia, leukopenia,Electrolyte disturbances: hypokalemia, hypomagnesemia, hyponatremia,Pulmonary toxicity: dyspnea, respiratory failure (rare),Prior to infusion: premedicate with antipyretics, antihistamines, and corticosteroids to reduce infusion reactions
Avoid contact with eyes, eyelids, and mucous membranes. If contact occurs, rinse thoroughly with water. Discontinue if local irritation or sensitization develops. Use with caution in patients with inflamed or broken skin due to increased absorption risk. Not for use on large areas of the body for prolonged periods.
Hypersensitivity to amphotericin B or any component of the formulation,Concurrent administration with other nephrotoxic drugs (e.g., cyclosporine, tacrolimus, aminoglycosides) unless benefit outweighs risk,Severe pre-existing renal impairment (relative contraindication; use only if no alternative)
Hypersensitivity to selenium sulfide or any component of the formulation. Do not use on broken or inflamed skin.
No known food interactions. Maintain adequate hydration.
No known food interactions.
Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. However, systemic fungal infections pose significant maternal and fetal risk if untreated. Use only if clearly needed.
Pregnancy Category D. First trimester: Associated with Ebstein's anomaly and other congenital heart defects; avoid if possible. Second and third trimesters: Risk of fetal hyperthyroidism or hypothyroidism, cranial synostosis, intellectual disability, and neonatal goiter if maternal hyperthyroidism is treated with this drug. Use only if clearly needed and maternal benefit outweighs fetal risk.
It is not known whether amphotericin B is excreted in human milk. Because many drugs are excreted in human milk and due to the potential for adverse effects in nursing infants, the decision to discontinue nursing or discontinue the drug should be made, taking into account the importance of the drug to the mother. M/P ratio unknown.
Excreted in human milk. M/P ratio not available. Potential for serious adverse reactions in nursing infants, including thyroid dysfunction and arrhythmias. Decision to discontinue nursing or drug based on importance of drug to mother.
No specific dosing adjustments are recommended for pregnancy. However, given the potential for renal impairment and electrolyte disturbances, close monitoring is warranted. Dose adjustments are primarily based on renal function, which may be altered in pregnancy.
Pregnancy may increase clearance of this drug; dose adjustments often not required, but individualize based on maternal thyroid function and clinical response. Lower doses may be needed to avoid fetal hypothyroidism.
Monitor renal function and electrolytes closely; premedicate with diphenhydramine and acetaminophen to reduce infusion-related reactions; do not mix with saline or other electrolytes; administer via in-line filter (5 micron) only; ensure adequate hydration to prevent nephrotoxicity.
EXSEL (selenium disulfide) 2.5% shampoo: Use twice weekly for 2 weeks, then once weekly for maintenance. Limit application to 5-10 minutes before rinsing. Avoid contact with eyes or broken skin. Can cause temporary hair discoloration (especially on bleached or permed hair). May stain jewelry and clothing. For dandruff and seborrheic dermatitis of the scalp.
This medication is given intravenously and may cause fever, chills, or rigors during infusion.,Report any breathing difficulty, chest pain, or severe reaction immediately.,You may receive pre-medications to reduce side effects.,Stay well hydrated unless instructed otherwise.,Blood tests will be required to monitor kidney function and electrolytes.
Shake bottle well before use.,Wet hair thoroughly before applying shampoo.,Apply enough shampoo to lather and massage into scalp for 2-3 minutes.,Leave on scalp for 5 minutes (up to 10 minutes) before rinsing thoroughly.,Rinse hair and scalp completely to avoid residue.,Use twice weekly for first 2 weeks, then once weekly as directed.,Avoid contact with eyes; if contact occurs, rinse thoroughly with water.,Do not use on broken or irritated skin.,Discontinue use and consult doctor if rash or irritation develops.,May stain clothing and jewelry; rinse thoroughly after use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABELCET vs EXSEL, answered by our medical review team.
ABELCET is a Polyene antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that increase membrane permeability, leading to leakage of intracellular ions and cell death. The lipid complex formulation (ABELCET) alters pharmacokinetics to reduce nephrotoxicity while retaining antifungal activity.. EXSEL is a Topical Antifungal that works by Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABELCET and EXSEL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABELCET is: 5 mg/kg IV once daily infused over 2-2.5 hours. For aspergillosis, duration is typically 2-4 weeks total.. The standard adult dose of EXSEL is: 1-2 mg orally once daily; maximum dose 2 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABELCET and EXSEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABELCET is classified as Category C. Pregnancy Category B. Animal studies with amphotericin B deoxycholate have shown no evidence of fetal harm. There are no adequate and well-controlled studies in pregnant women. How. EXSEL is classified as Category C. Pregnancy Category D. First trimester: Associated with Ebstein's anomaly and other congenital heart defects; avoid if possible. Second and third trimesters: Risk of fetal hyperthyr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.